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Respiratory syncytial virus (RSV) is a nonsegmented
negative-sense RNA virus that belongs to the Paramyxo-
viridae family of viruses. The genome encodes 11 pro-
teins. A ubiquitous human pathogen, RSV primarily in-
fects cells of the respiratory epithelium, inducing pulmo-
nary inflammation. RSV is the leading cause of
respiratory disease in infants and young children world-
wide, estimated to account for over 90,000 yearly hospi-
talizations in the United States alone (Heilman, 1990).
Direct viral cytopathology may play only a minor role in
the pathogenesis of RSV induced disease and it appears
that much of the injury caused by RSV infection may be
the result of the host immune/inflammatory response.
RSV infection of infants and young children often results
in acute bronchiolitis, leading to obstruction of the air-
ways that is associated with the inflammatory response
to infection. More recently, RSV has also been demon-
strated to be an important cause of severe respiratory
illness in elderly and immunocompromised individuals
(Dowell et al., 1996; Falsey et al., 1995, 1992; Harrington
et al., 1992; Mlinaric-Galinovic et al., 1996).
It is estimated that by the first two years of life virtually
all children have been exposed to the virus (Glezen et al.,
1986). However, RSV elicits an ineffective immune re-
sponse in humans that allows for repeated infections
throughout life. Although severe lower respiratory tract
disease is generally confined to infants or the elderly,
reinfections cause common colds and ear infections in
older children and adults. The development of a safe and
effective vaccine has been a priority due to the signifi-
cant health and economic burdens caused by RSV. Un-
fortunately, an initial formalin-inactivated RSV (FI-RSV)
vaccine trial conducted in very young children during the2031960s resulted in unexpected morbidity following natural
infection. The FI-RSV vaccine not only failed to protect
the vaccinated children from a naturally acquired RSV
infection, but also resulted in the development of en-
hanced lower respiratory tract disease that required hos-
pitalization among a subset of the vaccinated children
following a natural exposure to RSV (Belshe et al., 1982;
Chin et al., 1969; Fulginiti et al., 1969; Kapikian et al.,
1969; Kim et al., 1969). Subsequent studies showed that
the FI-RSV vaccine induced high titers of RSV neutraliz-
ing antibodies in the vaccine recipients, suggesting that
antibody alone could not confer complete protection to a
subsequent live RSV infection. Regrettably, several of the
FI-RSV vaccine recipients died following a natural expo-
sure to RSV and, upon autopsy, histological examination
of the lungs revealed peribronchiolar infiltration and in-
creased levels of eosinophils (Chin et al., 1969). In ret-
rospect, the presence of pulmonary eosinophilia sug-
gests that the FI-RSV vaccine may have primed for a
memory T cell response in the lungs, that after natural
infection, induced a potent Th2 cytokine response by the
memory/effector T cells.
There is currently no safe and effective licensed RSV
vaccine in part because the mechanism behind the FI-
RSV vaccine-enhanced disease remains poorly under-
stood. In addition, it is unclear what, if any, arms of the
immune system will provide the most beneficial host
response without priming for a memory response that
causes enhanced immunopathology such as that exhib-
ited by the FI-RSV vaccine recipients. Thus, a better
understanding of both the primary and the secondary
immune response to RSV is imperative before a safe and
successful vaccine can be developed.
Role of CD4 T cells
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cells in generating antiviral antibodies as well as secret-
ing cytokines such as IFN- and TNF-. In the wake of
the 1960s FI-RSV vaccine failure, several animal models
have been developed to study RSV vaccine-enhanced
disease. Of these models, the immune response to RSV
has been most extensively studied in BALB/c mice. Stud-
ies using the BALB/c model have demonstrated that
CD4 T cells can prove detrimental to the host by medi-
ating immunopathology and exacerbating disease (Al-
wan and Openshaw, 1993; Alwan et al., 1992; Graham et
al., 1991). For example, transfer of RSV G-specific Th2
CD4 T cell lines into naı¨ve recipients has been shown
to induce lung eosinophilia following intranasal RSV in-
fection (Alwan et al., 1994), a phenotype similar to that
exhibited by the subset of children who received the
FI-RSV vaccine and later developed enhanced disease
following natural RSV infection. The enhanced pulmo-
nary pathology exhibited by the children that received
the FI-RSV vaccine can also be simulated by priming
BALB/c mice either with FI-RSV (Connors et al., 1992;
Tang and Graham, 1994; Waris et al., 1996) or with a
recombinant vaccinia virus (vv) expressing the attach-
ment glycoprotein (G) of RSV (Openshaw et al., 1992)
followed by challenge infection with live RSV. BALB/c
mice sensitized with vvG develop extensive lung inflam-
mation characterized by pulmonary eosinophilia follow-
ing challenge infection with live RSV (Openshaw et al.,
1992). In contrast, BALB/c mice sensitized with vv ex-
pressing the fusion (F) or matrix (M2) proteins also de-
velop extensive pulmonary inflammation, characteristic
of a memory T cell response, but without lung eosino-
philia following RSV challenge infection (Openshaw et
al., 1992). These results can be explained in part be-
cause the G protein does not generate a detectable
MHC class I restricted CD8 T cell response but does
induce a strong memory G protein-specific CD4 T cell
response in the lungs characterized by a mixture of Th1
and Th2 cytokine-secreting cells (Srikiatkhachorn and
Braciale, 1997a,b, 1999). In contrast, the F protein in-
duces MHC class I-restricted CTL as well as Th1, but not
Th2, cytokine-producing CD4 T cells (Srikiatkhachorn
and Braciale, 1997b). Thus, these observations suggest
that that lung pathology and pulmonary eosinophilia in-
duced by FI-RSV or vvG immunization may result from the
selective priming of virus-specific CD4 T cells and im-
plicate Th2 cytokine production (i.e., IL-4, IL-5, and IL-13)
as an important factor in this disease process. These
and related data (Hussell et al., 1997) also suggest that a
concomitant CD8 T cell response to RSV infection can
modulate the development of a CD4 Th2 T cell re-
sponse in the infected lungs. Although it has been es-
tablished for some time that CD4 T cells directed
against the G protein can mediate enhanced pulmonary
injury (Alwan and Openshaw, 1993; Alwan et al., 1992),
the specificity, magnitude, and character of the G protein-
specific memory CD4 T cell response in lungs has only
recently been examined (Srikiatkhachorn et al., 1999;
Tripp et al., 2001; Varga et al., 2001, 2000).
In accordance with previous studies that suggested
the presence of one or more CD4 T cell epitopes within
the G protein of RSV (Sparer et al., 1998; Srikiatkhachorn
et al., 1999; Tebbey et al., 1998), recent work has dem-
onstrated that the G protein-specific memory CD4 T cell
response in BALB/c mice is directed against a single
I-Ed-restricted immunodominant epitope (Varga et al.,
2000). Interestingly, this single epitope elicits a memory
response yielding both Th1 and Th2 effector CD4 T
cells. Although most studies suggest that sensitization to
the G protein induces predominantly a Th2 response,
recent studies, using a combination of intracellular cyto-
kine analyses and ELISPOT assays to visualize individ-
ual cytokine-secreting RSV G peptide-specific CD4 T
cells, have shown that IFN--secreting Th1 CD4 T cells
predominate the RSV G protein-specific memory CD4 T
cell response in G-sensitized mice challenged with RSV
(Varga et al., 2001, 2000). It is currently unclear why a
small subset of the CD4 T cells specific to a single
immunodominant epitope within the G protein develops
into Th2 cytokine-secreting CD4 T cells despite the
presence of a high percentage of IFN--secreting Th1
CD4 T cells.
Recent work (Varga et al., 2001) has unexpectedly
demonstrated that the RSV G-specific CD4 T cell re-
sponse is highly restricted in the T cell receptor usage
during challenge infection with the majority of the lung
infiltrating RSV G-specific T cells among individual in-
fected recipients expressing V14. Moreover, the TCR 
chain complement-determining region 3 sequence of
these V14 CD4 T cells is remarkably conserved.
Short-term (6–24 h) in vitro activation of lung-derived
CD4 T cells isolated from vvG-primed mice undergoing
challenge RSV infection using a V14 TCR-specific mAb
results in the release of both Th1 and Th2 cytokines,
suggesting that CD4 T cells expressing a V14 TCR
directed against the immunodominant epitope can dif-
ferentiate into either Th1 or Th2 CD4 effector T cells in
vivo. Furthermore, in vivo depletion of the V14 T cells
either at sensitization with RSV G or at challenge infec-
tion significantly reduced systemic illness, weight loss,
and pulmonary eosinophilia following experimental RSV
infection (Varga et al., 2001). It is possible that this unique
oligoclonal CD4 T cell population may already be com-
mitted to develop along the Th2 pathway at the time of
initial encounter with antigen. This idea is supported by
previous work showing that primary immunization with a
synthetic peptide containing the immunodominant G
epitope results in pulmonary eosinophilia and enhanced
illness following challenge RSV infection (Tebbey et al.,
1998). In addition, a recent study examining the CD4 T
cell response elicited by repeated exposure to soluble
hen egg white lysozyme has demonstrated the selective
development of antigen-specific Th2 CD4 T cells that
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express the V14 T cell receptor (Foucras et al., 2002).
Since a soluble secreted form of RSV G can be gener-
ated and released from infected cells, it is possible that
this structural feature of the RSV G protein may favor Th2
CD4 T cell differentiation of naı¨ve precursor T cells.
Release of the G protein may also facilitate the develop-
ment of a strong CD4 T cell response through uptake,
processing, and presentation of the G epitope through
the MHC class II exogenous presentation pathway. Mice
primed with the secreted form of G exclusively have
been shown to develop greater eosinophilia, weight loss,
and systemic illness after RSV challenge than mice
primed with the membrane anchored form of G (Johnson
et al., 1998).
The demonstration of an oligoclonal T cell response
eliciting both Th1 and Th2 effector cells and capable of
mediating enhanced disease may have important impli-
cations for vaccine-induced enhanced injury in humans
since only a subset of the children who received the
FI-RSV vaccine in the early vaccine trial went on to
exhibit enhanced disease after natural RSV infection
(Belshe et al., 1982; Chin et al., 1969; Fulginiti et al., 1969;
Kapikian et al., 1969; Kim et al., 1969). It is possible that
the subset of vaccinated children that developed en-
hanced disease may also have mounted a narrowly
focused CD4 T cell response. It remains to be seen
whether FI-RSV immunized BALB/c mice also develop a
skewed V14 CD4 T cell response following RSV chal-
lenge infection.
Role of CD8 T cells
Although there is not a detectable CD8 T cell response
to the G protein of RSV, strong CD8 T cell responses are
elicited to several other proteins including M, N, and F
(Altman et al., 1996; Alwan and Openshaw, 1993; Open-
shaw et al., 1990). Several recent studies have demon-
strated that CD8 T cells play an important role in direct-
ing the type of inflammatory infiltrate into the lungs of G
protein-sensitized mice challenged with RSV. As men-
tioned above, adoptive transfer of RSV G-specific T cell
lines into BALB/c mice infected with RSV can reproduce
the pathology observed in mice sensitized with vvG (Al-
wan et al., 1994). Interestingly, cotransfer of M2-specific
CD8 T cells reduced the degree of pulmonary eosino-
philia induced by transfer of Th2-like G-specific CD4 T
cells (Alwan et al., 1994). Similarly, insertion of a MHC
class I restricted CD8 T cell epitope derived from the
M2 protein into the G protein used to prime a memory
CD4 T cell response prevented the development of
pulmonary eosinophilia following sensitization and RSV
challenge infection (Srikiatkhachorn and Braciale,
1997a).
Deletion of CD8 T cells in F-sensitized mice leads to
the development of pulmonary eosinophilia following live
RSV challenge infection. Further studies suggest that
IFN- production by the CD8 T cells is required to
prevent the induction of pulmonary eosinophilia by the
F-specific CD4 T cells (Hussell et al., 1997). It is cur-
rently unclear whether the IFN- produced by the CD8
T cells has a direct effect on the differentiation of the
F-specific CD4 T cells or if the IFN- is acting through
another cell type that interacts with the CD4 T cells.
Why the high level of IFN- produced by G-specific
memory CD4 T cell effectors during challenge RSV
infection does not down modulate the production of Th2
cytokines is currently not clear.
The direct visualization and quantitation of antigen-
specific T cell populations has been aided greatly by the
development of tetrameric complexes of MHC glycopro-
tein loaded with peptides as well as the ability to stain for
intracellular cytokines in cells stimulated with peptides
(Altman et al., 1996; Murali-Krishna et al., 1998). However,
in most of the systems studied to date, there is a good
correlation between the results obtained with tetramers
and intracellular IFN- staining (Doherty and Chris-
tensen, 2000; Murali-Krishna et al., 1998). Recent exam-
ination of the CD8 T cell response during RSV infection
has demonstrated that the M2-specific CD8 T cells
within the RSV infected lung are impaired in their expres-
sion of effector activity, including cytokine production
and ex vivo cytolytic activity (Chang and Braciale, 2002).
This impaired effector activity was not seen in other
peripheral lymphoid compartments such as the spleen,
where RSV cannot replicate. Furthermore, in vitro incu-
bation of the CD8 T cells in IL-2 prior to antigenic
stimulation restored the ability of the CD8 T cells to
make IFN- (Chang and Braciale, 2002). These results
suggest that the inhibition of CD8 T cell effector activity
is due to interference with T cell receptor signaling of the
RSV M2-specific CD8 T cells by one or more RSV gene
products. The exact mechanism of the inhibition remains
to be elucidated. However, these data as well as the
related finding that memory CD8 T cell development is
inhibited selectively in the lungs (Chang and Braciale,
2002) suggest that RSV may also suppress or alter the
host response to infection resulting in the impairment of
immunological memory. The ability of RSV to selectively
inhibit the development of durable immunological mem-
ory in the respiratory tract (but not in secondary lymphoid
organs) after infection (Chang and Braciale, 2002) may in
part explain one of the major paradoxes of RSV infection,
that is, the continued susceptibility of humans to repeat
infection with the virus despite past exposure.
CONCLUSIONS
Recent work in the murine model has shown that RSV
vaccine-enhanced immunopathology is uniquely re-
stricted to a discrete oligoclonal CD4 T cell population,
suggesting that the commitment of virus-specific CD4 T
cells to Th2 differentiation may be dictated by TCR usage
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and regulated by genetic or environmental factors oper-
ating on the naı¨ve CD4 T cells at the time of initial
exposure to specific viral antigen. These results raise the
possibility that the enhanced pulmonary injury observed
by the FI-RSV vaccine recipients after natural RSV infec-
tion may have been due to the induction of a memory
CD4 T cell population with limited TCR diversity that
may be programmed to differentiate into Th2 cytokine-
secreting effectors in response to natural RSV infection.
Recent analyses of the CD8 T cell response to RSV in
the lungs suggests that the one or more RSV gene
products can impact the ability of the RSV-specific CD8
T cell to exhibit effector activity such as IFN- secretion
and perforin-mediated lysis. These recent studies high-
light the interplay between the virus and its gene prod-
ucts and the host immune response and how altering
this fine balance can impact the severity of disease in
the infected host. Taken together, these recent findings
strongly suggest that further analysis of the specificity,
effector activity, and repertoire diversity of RSV-specific T
cells in the respiratory tract during human RSV infection
will be necessary to gain a better understanding of
RSV-induced immunopathology. Furthermore, the recent
finding that pulmonary RSV infection impairs T cell effec-
tor function and the formation of durable memory T cell
responses in the lung but not in central lymphoid tissue
(i.e., spleen and lymph nodes) has important implications
for human RSV infection. These data suggest that eval-
uating effector/memory compartments (e.g., peripheral
blood) may not provide an adequate assessment of the
host response to RSV. Rather, techniques need to be
developed to monitor the magnitude and character of the
effector and memory immune response in the respiratory
tract where RSV replication is maximal and where RSV-
induced immune dysfunction is localized.
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